ClinicalTrials.Veeva

Menu

Proteiomic Fingerprints of Gastric Juice

K

Kaohsiung Veterans General Hospital

Status

Completed

Conditions

Gastric Cancer

Treatments

Other: normal subject
Other: gastric cancer

Study type

Interventional

Funder types

Other

Identifiers

NCT00834236
VGHKS96-CT2-24

Details and patient eligibility

About

No accurate, inexpensive and non-invasive test for gastric cancer screening is currently available. The investigators' recent study identified a1-antitrypsin and other proteins as potential biomarkers of gastric cancer in gastric juice. The aim of this study was to develop a novel non-invasive modality for detecting gastric cancer by measurement of biomarkers in gastric juice.

Full description

Patients and methods: The study consisted of two parts: (1) investigating the differences in gastric juice biomarker concentrations between gastric cancer patients and controls, and (2) screening gastric cancer using string test to obtain gastric juice followed by immunoassay for biomarker concentration.

Enrollment

76 patients

Sex

All

Ages

18 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy subjects and gastric cancer patients documented by endoscopy.

Exclusion criteria

  • the use of proton pump inhibitors or histamine-2 receptor antagonists within 4 weeks prior to the study
  • coexistence of two kinds of gastroduodenal lesions
  • coexistence of severe systemic diseases

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

76 participants in 2 patient groups

gastric cancer
Experimental group
Description:
gastric cancer patients
Treatment:
Other: gastric cancer
Other: normal subject
normal subject
Active Comparator group
Description:
healthy subject
Treatment:
Other: gastric cancer
Other: normal subject

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems